Neonatal Screening (Total Galactose)

The Neonatal Screening (Total Galactose) test is a newborn blood screening test that measures total galactose to identify babies who may be at increased risk of galactosemia or another disorder affecting galactose metabolism. Galactosemia is a group of rare inherited metabolic conditions in which the body cannot properly process galactose, a simple sugar obtained mainly from lactose in breast milk, standard infant formula and other milk products.

A newborn with galactosemia may initially appear healthy. However, galactose and related substances can accumulate after milk feeding begins and may cause serious health complications. Early screening helps identify babies who require urgent clinical evaluation and confirmatory testing. This test is a screening investigation and cannot independently establish or exclude a diagnosis of galactosemia.

What Is Galactose?

Galactose is a simple sugar that forms part of lactose. When a baby consumes breast milk or a lactose-containing formula, lactose is broken down into glucose and galactose. The body then uses a series of enzymes to convert galactose into substances that can be used for energy.

If one of the enzymes involved in this pathway is absent or has reduced activity, the baby may be unable to process galactose normally. Galactose or its metabolites may consequently accumulate in the blood and tissues. Depending on the enzyme affected and the severity of the deficiency, this accumulation can affect the liver, kidneys, eyes, nervous system and other organs.

What Does the Total Galactose Screening Test Measure?

The test measures total galactose in a newborn's dried blood spot specimen. Depending on the laboratory method, total galactose may represent free galactose together with galactose-1-phosphate. An increased concentration can indicate that the baby's galactose-processing pathway is not functioning normally.

Total galactose screening may help detect classical galactosemia and certain related disorders. However, the marker is not specific enough to determine the exact enzyme deficiency. An out-of-range result must therefore be followed by appropriate diagnostic testing, which may include red-blood-cell enzyme activity, quantitative galactose-1-phosphate measurement, liver-function tests, urine investigations and molecular genetic testing.

Conditions Associated with Increased Total Galactose

Classical Galactosemia

Classical galactosemia, also called galactosemia type I, is usually caused by severely reduced activity of the galactose-1-phosphate uridylyltransferase enzyme, commonly abbreviated as GALT. When GALT activity is deficient, galactose-1-phosphate and other metabolites can accumulate after lactose-containing feeds begin.

Untreated classical galactosemia can become medically serious during the neonatal period. Possible features include poor feeding, vomiting, lethargy, jaundice, liver enlargement, abnormal liver function, low blood glucose, bleeding problems, failure to gain weight and serious infection. Early clinical management can reduce the risk of acute complications, making prompt follow-up of an abnormal screen essential.

Galactokinase Deficiency

Galactokinase deficiency, also known as galactosemia type II, affects a different step in galactose metabolism. It may be associated particularly with cataract formation caused by the accumulation of galactitol in the lens of the eye. The clinical presentation can differ from classical galactosemia, and specialised biochemical or genetic testing is required to identify the exact disorder.

Galactoepimerase Deficiency

UDP-galactose 4-epimerase deficiency, sometimes called galactosemia type III, has a variable clinical spectrum. Some individuals have an enzyme deficiency largely limited to blood cells, while others may have a more generalised condition. Because different disorders can produce abnormal galactose-related markers, a newborn should not be assigned a specific diagnosis based only on total galactose screening.

Why Is Neonatal Total Galactose Screening Important?

Newborn screening is important because an affected baby may not show obvious signs immediately after birth. Symptoms can appear after exposure to breast milk or standard infant formula because both normally contain lactose. In severe galactosemia, a baby's health may deteriorate within the first days of life.

Screening provides an opportunity to recognise biochemical risk before complications progress. An abnormal result can lead to rapid communication with the baby's paediatrician, diagnostic testing and specialist management. Screening does not prevent the condition, but it can shorten the time required to recognise babies who need further care.

Who May Need This Test?

The test may be performed as part of routine neonatal screening, even when the baby appears healthy and there is no known family history of galactosemia. Inherited metabolic disorders can occur in families with no previously diagnosed cases because parents may be healthy carriers of a disease-associated genetic variant.

A doctor may particularly consider screening or diagnostic evaluation when a newborn has persistent jaundice, vomiting, poor feeding, lethargy, inadequate weight gain, an enlarged liver, abnormal liver-function results, low blood glucose, cataracts, unexplained bleeding or suspected neonatal infection. These features can have many different causes and do not by themselves confirm galactosemia.

Babies with a sibling or relative affected by galactosemia may require a planned diagnostic pathway rather than reliance on routine screening alone. Parents should inform the obstetric, neonatal and paediatric teams about any known family history before or immediately after delivery.

Sample Required for the Test

The usual specimen is a dried blood spot collected from the newborn's heel. A trained healthcare professional cleans the heel, uses a sterile lancet and applies several drops of blood to marked circles on a specialised filter-paper card. The blood must soak through the paper correctly, after which the card is allowed to dry and is transported to the laboratory.

Accurate collection is essential. A sample may be unsuitable if it contains insufficient blood, overlapping drops, contamination, excessive tissue fluid, moisture or incomplete saturation of the collection circles. An unsuitable specimen may delay screening and require recollection.

When Should the Sample Be Collected?

Newborn blood spot screening is commonly performed after approximately 24 to 48 hours of life, although the appropriate timing depends on the laboratory protocol, the baby's health and the applicable newborn screening programme. Because total galactose can be influenced by exposure to milk, the timing of feeding and sample collection should be recorded accurately.

If a baby is discharged early, born prematurely, seriously ill, receiving parenteral nutrition or tested before the recommended collection time, repeat screening may be advised. Screening should not be delayed in a baby with concerning symptoms. A symptomatic newborn requires immediate medical assessment regardless of whether a routine screening specimen has already been collected.

Preparation Before Sample Collection

No fasting is generally required. Parents should not stop breastfeeding or change the baby's formula before the test unless the treating paediatrician gives specific instructions. The collection team should be informed about the baby's date and time of birth, gestational age, birth weight, feeding status, clinical condition, medicines, transfusions and relevant family history.

Parents should also mention whether the baby is receiving a lactose-free or galactose-restricted feed. Limited exposure to lactose before collection may influence galactose-related measurements and must be considered when interpreting the result.

Understanding the Test Result

Screen-Negative or In-Range Result

An in-range result means the measured total galactose did not exceed the laboratory's screening threshold in the submitted specimen. It reduces the likelihood of a condition that produces significant galactose elevation at the time of testing, but it does not guarantee that every form of galactosemia has been excluded.

Screening sensitivity depends on the disorder, analytical method, cut-off, specimen quality, feeding history and timing of collection. A baby with symptoms or a strong family history may still need diagnostic testing even after an in-range screening result.

Screen-Positive or Out-of-Range Result

An increased total galactose result means that additional assessment is required. It does not prove that the baby has classical galactosemia or any other specific disorder. False-positive results can occur, and galactose elevation may be associated with alternative metabolic or medical explanations.

Because classical galactosemia can cause serious illness shortly after birth, an out-of-range result should be communicated and evaluated without delay. The paediatrician or metabolic specialist will decide which confirmatory tests are required and whether any temporary clinical measures are appropriate while confirmation is pending.

Possible Confirmatory Investigations

Follow-up testing may include measurement of GALT enzyme activity in red blood cells, quantitative galactose-1-phosphate, plasma galactose, urinary galactitol or reducing substances, liver-function tests, coagulation studies, glucose testing and molecular analysis of relevant genes. The specific investigations depend on the screening value, the baby's symptoms, transfusion history and local clinical protocol.

Recent transfusion can affect enzyme testing performed on red blood cells because donor cells may contain normal enzyme activity. The clinical team should know whether the baby received packed cells or an exchange transfusion and when it occurred. Genetic testing may be especially useful when enzyme testing is difficult to interpret.

Factors That Can Influence Results

• Collection before adequate milk feeding or very early after birth
• Use of lactose-free or galactose-restricted feeds before collection
• Prematurity, low birth weight or serious neonatal illness
• Liver dysfunction from another medical condition
• Recent blood or exchange transfusion
• Delayed sample transport or exposure to excessive heat
• Insufficient, contaminated or improperly dried blood spots
• Differences between laboratory methods and screening thresholds

Limitations of Total Galactose Screening

Total galactose is a screening marker rather than a disease-specific diagnosis. The test may identify biochemical risk but cannot determine the exact genetic variant, enzyme deficiency, clinical severity or long-term outcome. Some variants may produce mild, intermittent or minimal galactose elevation and may not be detected by a total-galactose-only strategy.

A result must be interpreted together with the baby's age, feeding history, symptoms, specimen quality and additional investigations. Screening does not replace a paediatric examination, specialist metabolic assessment or diagnostic testing when clinically indicated.

What Happens If Galactosemia Is Confirmed?

Management depends on the type and severity of the confirmed disorder. Classical galactosemia usually requires specialised dietary management that restricts galactose and lactose. The paediatrician and metabolic dietitian select an appropriate feeding plan and monitor the baby's growth, nutrition, liver function and development.

Parents should not independently stop breast milk or introduce a different formula solely because they suspect galactosemia or receive an unconfirmed result. However, when a screening result is strongly abnormal, the clinical team may recommend immediate temporary dietary changes while confirmatory testing is completed. Such decisions must be made urgently by qualified healthcare professionals.

When Is Urgent Medical Attention Required?

Seek urgent medical care if a newborn develops poor feeding, repeated vomiting, worsening jaundice, unusual sleepiness, reduced responsiveness, fever, low body temperature, breathing difficulty, seizures, bleeding, abdominal swelling, dehydration or failure to wake for feeds. Do not wait for a screening report when a baby appears unwell.

Important Clinical Note

A positive neonatal screen is not a confirmed diagnosis, but it should never be ignored. Prompt follow-up is important because severe galactosemia may cause complications very early in life. Similarly, a negative screen should not delay clinical investigation when the baby has concerning symptoms or a known family history.

Booking Neonatal Screening (Total Galactose)

The Neonatal Screening (Total Galactose) test is available through Focus Diagnostics for ₹350. Before collection, confirm the recommended timing, specimen requirements, reporting schedule and urgent-result communication process. This information is provided for education and should not replace personalised guidance from the newborn's paediatrician, neonatologist or metabolic specialist.